These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 17675761)

  • 1. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
    Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
    Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
    Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term follow up after antithyroid drug treatment in Graves' disease].
    Wille T; Müller B; Noth D; Bürgi U; Diem P
    Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
    J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
    Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
    Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
    García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
    Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.